IMRN vs. PPBT, KPRX, RDHL, ERNA, IMNN, PIRS, HUGE, EDSA, AKTX, and MNPR
Should you be buying Immuron stock or one of its competitors? The main competitors of Immuron include Purple Biotech (PPBT), Kiora Pharmaceuticals (KPRX), RedHill Biopharma (RDHL), Eterna Therapeutics (ERNA), Imunon (IMNN), Pieris Pharmaceuticals (PIRS), FSD Pharma (HUGE), Edesa Biotech (EDSA), Akari Therapeutics (AKTX), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical preparations" industry.
Purple Biotech (NASDAQ:PPBT) and Immuron (NASDAQ:IMRN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.
Immuron received 174 more outperform votes than Purple Biotech when rated by MarketBeat users. However, 92.86% of users gave Purple Biotech an outperform vote while only 67.75% of users gave Immuron an outperform vote.
Purple Biotech's return on equity of 0.00% beat Immuron's return on equity.
Purple Biotech presently has a consensus price target of $9.00, indicating a potential upside of 1,536.36%. Given Immuron's higher possible upside, equities research analysts plainly believe Purple Biotech is more favorable than Immuron.
9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by insiders. Comparatively, 7.0% of Immuron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Purple Biotech had 1 more articles in the media than Immuron. MarketBeat recorded 1 mentions for Purple Biotech and 0 mentions for Immuron. Immuron's average media sentiment score of 0.00 equaled Purple Biotech'saverage media sentiment score.
Purple Biotech has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Immuron has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500.
Immuron has higher revenue and earnings than Purple Biotech.
Summary
Immuron beats Purple Biotech on 7 of the 12 factors compared between the two stocks.
Get Immuron News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
